Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Medicis Pharmaceutical Corp    MRX

SummaryNewsCompany 
News SummaryMost relevantAll newsSector news 

Medicis Pharmaceutical Corp : Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 01:55pm CEST

MONTREAL, Nov. 16, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Medicis Pharmaceutical Corporation (NYSE: MRX) by Valeant and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) without conditions. The grant of early termination is effective as of November 15, 2012.

The proposed merger remains subject to other customary closing conditions, including the approval of the Medicis's stockholders at its special meeting of stockholders scheduled for December 7, 2012. The Company expects to close the merger within four business days following satisfaction of all closing conditions.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

These forward-looking statements relate to, among other things, the expected timing of the close of the transaction. Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things, the expected timing of the close of the transaction and the satisfaction of the closing conditions to the transaction, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA").

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

SOURCE Valeant Pharmaceuticals International, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDICIS PHARMACEUTICAL COR
03/21 TIMELINE : Shakeup at Valeant as longtime CEO Pearson leaving
2015 From pilot to profit-maker, Valeant's pharmacy rose quickly
2012DJGarmin to Join S&P 500 Index, Replacing RR Donnelley
2012 MEDICIS PHARMACEUTICAL CORP : Valeant Pharmaceuticals Announces New Management A..
2012 MEDICIS PHARMACEUTICAL CORP : Valeant Pharmaceuticals Receives FTC Clearance For..
2012DJMedicis Pharma Shares Fall on Q-Med Lawsuit
2012 MEDICIS PHARMACEUTICAL CORP : Medicis Declares Cash Dividend
2012 MEDICIS PHARMACEUTICAL CORP : Law Office of Brodsky & Smith, LLC Announces Inves..
2012 MEDICIS PHARMACEUTICAL CORP : Faruqi & Faruqi, LLP Is Seeking More Cash For The ..
2012DJU.S. HOT STOCK FUTURES : Hot stocks to watch
More news
Sector news : Generic Pharmaceuticals
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Generic Pharmaceuticals